Skip to main content
SpringerLink
Log in

Annual Congress of the European Society for Medical Oncology (ESMO): Munich, Germany, 19–23 October 2018

  • Meeting Report
  • Published:
Targeted Oncology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Denkert C, Liedtke C, Tutt A, von Minckwitz G. Molecular alterations in triple-negative breast cancer—the road to new treatment strategies. Lancet. 2017;389:2430–42.

    Article  CAS  Google Scholar 

  2. Robson M, Im SA, Senkus E, Xu B, Domcheck SM, Masuda N, et al. Olaparib for metastatic breast Cancer in patients with a germline BRCA mutation. N Engl J Med. 2017;377:523–33.

    Article  CAS  Google Scholar 

  3. Litton JK, Tugo HS, Ettl J, Hurvitz SA, Gonçalves A, Lee KH, et al. Talazoparib in patients with advanced breast Cancer and a germline BRCA mutation. N Engl J Med. 2018;379:753–63.

    Article  CAS  Google Scholar 

  4. Clarke JM, George DJ, Lisi S, Salama AKS. Immune checkpoint blockade: the new frontier in Cancer treatment. Target Oncol. 2018;13(1):1–20.

    Article  Google Scholar 

  5. Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast Cancer. N Engl J Med. 2018. https://doi.org/10.1056/NEJMoa1809615.

  6. Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, et al. IMpassion130: Results from a global, randomised, double-blind, phase 3 study of atezolizumab (atezo) + nab-paclitaxel (nab-P) vs placebo + nab-P in treatment-naive, locally advanced or metastatic triple-negative breast cancer (mTNBC). Ann Oncol. 2018;29(suppl_8) LBA1_PR.

  7. Vijayaraghavan S, Moulder S, Keyomarsi K, Layman RM. Inhibiting CDK in Cancer therapy: current evidence and future directions. Target Oncol. 2018;13:21–38.

    Article  Google Scholar 

  8. Cristofanilli M, Turner NC, Bondarenko I, Ro J, Im SA, Masuda N, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol. 2016;17:425–39.

    Article  CAS  Google Scholar 

  9. Pfizer Announces Overall Survival Results from Phase 3 PALOMA-3 Trial of IBRANCE® (Palbociclib) in HR+, HER2- Metastatic Breast Cancer. Press release 25 June 2018. https://www.pfizer.com/news/press-release/press-release-detail/pfizer_announces_overall_survival_results_from_phase_3_paloma_3_trial_of_ibrance_palbociclib_in_hr_her2_metastatic_breast_cancer-0.

  10. Turner NC, Slamon DJ, Ro J, Bondarenko I, Im SA, Masuda N, et al. Overall survival with Palbociclib and Fulvestrant in advanced breast Cancer. N Engl J Med. 2018 Oct 20. https://doi.org/10.1056/NEJMoa1810527.

  11. Cristofanilli M, Slamon DJ, Ro J, Bondarenko I, Im SA, Masuda N. Overall survival (OS) with palbociclib plus fulvestrant in women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) advanced breast cancer (ABC): Analyses from PALOMA-3. Ann Oncol. 2018;29(suppl_8) LBA2_PR.

  12. Araki K, Miyoshi Y. Mechanism of resistance to endocrine therapy in breast cancer: the important role of PI3K/Akt/mTOR in estrogen receptor-positive, HER2-negative breast cancer. Breast Cancer. 2018;25:392–401.

    Article  Google Scholar 

  13. Baselga J, Dent SF, Cortés J, Im YH, Diéras V, Harbeck N, et al. Phase III study of taselisib (GDC-0032) + fulvestrant (FULV) v FULV in patients (pts) with estrogen receptor (ER)-positive, PIK3CA-mutant (MUT), locally advanced or metastatic breast cancer (MBC): Primary analysis from SANDPIPER. J Clin Oncol. 2018;36(suppl_18) LBA1006.

  14. André F, Ciruelos EM, Rubovszky G, Campone M, Loibl S, Rugo HS, et al. Alpelisib (ALP) + fulvestrant (FUL) for advanced breast cancer (ABC): results of the Phase 3 SOLAR-1 trial. Ann Oncol. 2018;29(suppl_8) LBA3_PR.

  15. Kumbla RA, Figlin RA, Posadas EM. Recent advances in the medical treatment of recurrent or metastatic renal cell Cancer. Drugs. 2017;77:17–28.

    Article  CAS  Google Scholar 

  16. Flippot R, Escudier B, Albiges L. Immune checkpoint inhibitors: toward new paradigms in renal cell carcinoma. Drugs. 2018;78:1443–57.

    Article  CAS  Google Scholar 

  17. Motzer RJ, Penkov K, Haanen JBAG, Rini BI, Albiges L, Campbell MT, et al. JAVELIN Renal 101: A randomized, phase III study of avelumab + axitinib vs sunitinib as first-line treatment of advanced renal cell carcinoma (aRCC). Ann Oncol. 2018;29(suppl_8) LBA6_PR.

  18. Merck’s KEYTRUDA® (pembrolizumab) in Combination with Pfizer’s Inlyta® (axitinib) Significantly Improved Overall Survival (OS) and Progression-free Survival (PFS) as First-Line Therapy for Advanced or Metastatic Renal Cell Carcinoma. Press release 18 October 2018. https://investors.merck.com/news/press-release-details/2018/Mercks-KEYTRUDA-pembrolizumab-in-Combination-with-Pfizers-Inlyta-axitinib-Significantly-Improved-Overall-Survival-OS-and-Progression-free-Survival-PFS-as-First-Line-Therapy-for-Advanced-or-Metastatic-Renal-Cell-Carcinoma/default.aspx.

  19. O’Sullivan Coyne G, Chen AP, Meehan R, Doroshow JH. PARP inhibitors in reproductive system cancers: current use and developments. Drugs. 2017;77:113–30.

    Article  Google Scholar 

  20. Moore K, Colombo N, Scambia G, Kim BG, Oaknin A, Firedlander M, et al. Maintenance Olaparib in patients with newly diagnosed advanced ovarian Cancer. N Engl J Med October. 2018;21. https://doi.org/10.1056/NEJMoa1810858.

  21. Moore KN, Colombo N, Scambia G, Kim BG, Oaknin A, Firedlander M, et al. Maintenance olaparib following platinum-based chemotherapy in newly diagnosed patients (pts) with advanced ovarian cancer (OC) and a BRCA1/2 mutation (BRCAm): Phase III SOLO1 trial. Ann Oncol. 2018;29(suppl_8) LBA7_PR.

  22. Moreira J, Tobias A, O’Brien MP, Agulnik M. Targeted therapy in head and neck Cancer: an update on current clinical developments in epidermal growth factor receptor-targeted therapy and immunotherapies. Drugs. 2017;77:843–57.

    Article  CAS  Google Scholar 

  23. Burtness B, Harrington KJ, Greil R, Soulières D, Tahara M, De Castro G. KEYNOTE-048: Phase III study of first-line pembrolizumab (P) for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). Ann Oncol. 2018;29(suppl_8) LBA8_PR.

Download references

Acknowledgements

The author would like to thank the European Society for Medical Oncology for the opportunity to attend this congress.

Author information

Authors and Affiliations

  1. Springer, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand

    Martin Chopra

Authors
  1. Martin Chopra
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Martin Chopra.

Ethics declarations

Funding

No funding was received for the preparation of this meeting report.

Conflict of Interest

Martin Chopra is a salaried employee of Adis/Springer, is responsible for the article content, and has no conflict of interest that might be relevant to the contents of this report.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Chopra, M. Annual Congress of the European Society for Medical Oncology (ESMO): Munich, Germany, 19–23 October 2018. Targ Oncol 13, 673–677 (2018). https://doi.org/10.1007/s11523-018-0608-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11523-018-0608-8

Search

Navigation